Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-007: Olaparib + Pembrolizumab in HRRm/HRD-Positive Advanced Solid Tumors
jRCT2011200025Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in Nonhematologic neoplasms, sponsored by Merck & Co. Primary endpoint: Confirmed objective response rate. Started Apr 2021; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2011200025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200025.